NVIV
InVivo Therapeutics Holdings Corp. [NVIV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVIV Stock Summary
In the News
NVIV Financial details
Company Rating
-
Market Cap
995.92K
Income
-8.98M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-0.27
Forward P/E
-
PEG
0.05
P/S
-
P/B
0.27
P/C
-
P/FCF
-0.24
Quick Ratio
12.88
Current Ratio
14.3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.7
EPS next Y
-
EPS next Q
-
EPS this Y
-11.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
40.32%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-94%
ROE
-72%
ROC
-1.09%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.22-2.4
52W High
-
52W Low
-
RSI
-
Rel Volume
0.43
Avg Volume
3.77M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.658
-
-
Volatility
0.03%, 0.03%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 3.77M
- Market Capitalization 995.92K
- Employee 6
- CEO Dr. Richard M. Toselli M.D.
- Headquarters Cambridge,MA,US
- IPO Date 2010-11-15
-
Website
https://www.invivotherapeutics.com 
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
